Evidence map›Paper›PMID 42281954›Full record

ArticleMolecular therapy. Oncology2026

Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibition.

Branka Radic-Sarikas, Marica Markovic, Martha Magdalena Zylka, Caterina Sturtzel, Mathias Ilg, Didier Surdez, Martin Metzelder, Martin Distel, Aleksandr Ovsianikov, Florian Halbritter and 1 more

Abstract read
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Branka Radic-SarikasSt. Anna Children's Cancer Research Institute (CCRI), 1090 Vienna, Austria.
Marica MarkovicInstitute of Materials Science and Technology, Technische Universität Wien (TU Wien), 1040 Vienna, Austria.
Martha Magdalena ZylkaSt. Anna Children's Cancer Research Institute (CCRI), 1090 Vienna, Austria.
Caterina SturtzelSt. Anna Children's Cancer Research Institute (CCRI), 1090 Vienna, Austria.
Mathias IlgSt. Anna Children's Cancer Research Institute (CCRI), 1090 Vienna, Austria.
Didier SurdezInserm U830, Équipe Labellisée INCC, PSL Université, SIREDO Oncology Centre, Institut Curie, Paris, France.
Martin MetzelderDepartment of Pediatric and Adolescent Surgery, Medical University of Vienna, 1090 Vienna, Austria.
Martin DistelSt. Anna Children's Cancer Research Institute (CCRI), 1090 Vienna, Austria.
Aleksandr OvsianikovInstitute of Materials Science and Technology, Technische Universität Wien (TU Wien), 1040 Vienna, Austria.
Florian HalbritterSt. Anna Children's Cancer Research Institute (CCRI), 1090 Vienna, Austria.
Heinrich KovarSt. Anna Children's Cancer Research Institute (CCRI), 1090 Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone sarcomas are rare and aggressive pediatric cancers with limited progress in targeted therapy development, partly due to the poor physiological relevance of conventional two-dimensional (2D) culture systems used for preclinical testing. To address this gap, we developed a standardized three-dimensional (3D) culture and drug-testing platform for Ewing sarcoma (ES) and osteosarcoma (OS) that more accurately recapitulates

Indexed as

3D cultureBCL-xL inhibitiondrug synergyEwing sarcomametabolic vulnerabilitiesmevalonate pathwayosteosarcomapatient-derived xenografts PDXspheroidsstatins

Identifiers

PMID42281954
PMCPMC13251664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.